Truist Securities Maintains Buy on SI-BONE, Lowers Price Target to $17

Truist Securities analyst David Rescott maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $20 to $17.

byBenzinga Newsdesk

December 20, 2022

1 minute read

Truist Securities analyst David Rescott maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $20 to $17.

Incannex Reveals Clinical Trial Results On Dronabinol-Based Drug For Obstructive Sleep Apnea

By Vuk Zdinjak

Today, 5:27 AM

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, has completed an analysis of data from the Phase 2 proof-of-concept clinical trial invest

IXHL

LumiraDx Announces Proposed Public Offering Of 40M Shares

By Benzinga Newsdesk

Today, 5:27 AM

LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering of 40,000,000 common shares. All of the shares in the

LMDX